INTRODUCTION
This is an interim report on an on-going study of a special population of subjects. Most case studies have weaknesses that good experimental research does not have, and this study is no exception. Nevertheless, we believe that the outcomes to date are worth bringing to the attention of others interested in otoacoustic emissions ͑OAEs͒ ͓see Probst et al. ͑1991͒ for a review͔ and sex differences in the auditory system ͓see McFadden ͑1998͒ for a review͔.
Females have more spontaneous otoacoustic emissions ͑SOAEs͒ and stronger click-evoked otoacoustic emissions ͑CEOAEs͒ than do males ͑Talmadge et al., 1993; McFadden et al., 1996͒ , and this difference exists in infants as well as adults ͑Burns et al., 1992; Norton, 1992͒ . In recent times, this laboratory has been interested in the origin of this and other auditory sex differences. We have shown that females having male co-twins ͑opposite-sex dizygotic or OSDZ twins͒ have OAEs that are more like those of males than those of other females ͑McFadden, 1993; McFadden et al., 1996͒. Further, the CEOAEs of homosexual females are significantly weaker ͑the male direction͒ than those of heterosexual females ͑McFadden and Pasanen, 1998͒. Our working hypothesis is that prenatal exposure to high levels of androgens leads to weaker cochlear amplifiers ͑Davis, 1983͒, and thus to fewer SOAEs and weaker CEOAEs.
Transsexuals taking sex hormones to alter their bodily appearance present an opportunity to study further the effects of hormones on the auditory system. Two such subjects have been recruited to date. Both are genetic and phenotypic males who are taking estrogenic hormones prior to undergoing sex-reversal surgery.
I. METHOD
Both subjects were recruited by referrals from local psychologists and physicians who oversee the pre-surgical treatment of such patients. Attempts to recruit additional subjects continue.
One subject, JF, was 34 years old at the onset of testing. He was married to women twice, and is the father of one child. Unfortunately, subject JF had already started hormone therapy several months prior to our first measurement session, so no true pre-drug baseline exists for him.
Of primary interest here is the other subject, DJ, who was 50 years old at the onset of testing. He has been married to three women for 4, 11, and 15 years each, but fathered no children because of a low sperm count. One test session was completed for subject DJ prior to his beginning drug treatment. He began taking estropipate ͑crystalline estrone sulfate stabilized with piperazine͒ in mid-August 1996 at a dose of 0.75 mg daily. The dose was doubled in November 1996 and doubled again in June 1997. ͓In early July 1997, 50 mg daily of spironolactone ͑Aldactone͒ was added, and that dose was doubled in mid-August 1997, when 5 mg daily of medroxyprogesterone was also added.͔ Throughout the test series, subject DJ was taking 2.5 mg of glyburide twice daily for diabetes. Subject DJ's serum testosterone level was 340 ng/dl prior to beginning estrogen therapy and it had fallen to 289 ng/dl in June 1997 ͑normal range for males is 241-826 ng/dl͒. With treatment, subject DJ noted decreased speed of growth of body hair, softer skin, development of the breasts, and increased hip size. Also, subject DJ has recently experienced a strong attraction to a male for the first time in his life. A hearing screening test conducted prior to his beginning estropipate revealed hearing losses of about 25, 45, and 65 dB at 3, 4, and 6 kHz, respectively, in the left ear, and losses of about 25 and 45 dB at 4 and 6 kHz, respectively, in the right ear.
Experimental sessions were approximately 2 h in length. SOAEs and CEOAEs were measured in both ears during each test session. For SOAEs, four to eight 30-s digital recordings were obtained of the acoustic waveform in the external ear canal. Sampling was 16-bit at 22.05 kHz. The rms level was calculated for 185.8-ms time segments whose onsets were delayed successively by increments of 46.4 ms ͑75% overlap͒. The quietest 500 of these time segments were shaped with a Hanning window function and then used to calculate 4k-point FFTs. The resulting squared magnitudes were summed to create the spectra shown in Fig. 1 CEOAEs, data were collected for four click levels ranging from 57 to 75 dB peak equivalent SPL ͑see McFadden and Pasanen, 1998͒ in 6-dB steps. At each level, the responses to 250 clicks were averaged. The presentation rate of the clicks was nominally ten per second, but the sound level in the canal was monitored continually and no click was presented until the noise level was below a criterion value. Thus the presentation rate varied, depending upon the noisiness of the subject ͑for additional detail see McFadden and Pasanen, 1998͒.
II. RESULTS
The OAEs of subject JF, for whom no pre-drug baseline existed, never exhibited SOAEs and showed no changes in his CEOAEs over the course of 13 months of repeated testing. Consequently, no data are shown for this subject.
For subject DJ, some changes did appear, but as noted at the outset, the data are not without flaws. Figure 1 shows the spectra obtained from the time samples collected from the right ear for successive test sessions. The most recent data are shown at the bottom of these figures, where the SOAEs have been marked with perpendicular dotted lines. Those same dotted lines have been added to the other panels in each figure to facilitate comparisons. Figure 1 shows that the right ear contained easily identifiable SOAEs in later sessions where none had been clearly evident in the earliest sessions. As noted, subject DJ began estrogen therapy in mid-August 1996, and the dose was doubled in November 1996 and doubled again in June 1997. Thus both of the test sessions at the top of Fig. 1 can be used for comparison with the later sessions; the first was truly pre-drug and the second was measured soon after a low dose of the drug was begun. A parallel series of spectra for the left ear revealed generally similar effects. A single weak SOAE was present in the baseline measures, and its level increased slightly after the beginning of estrogen administration.
Some of the problems with these data arise from the fact that the waveforms collected from some test sessions were quite noisy. As a consequence, those spectra were elevated to an extent that obscured any SOAEs that might have existed. In one case, the entire spectrum was elevated ͑23 October 1996, right ear͒, rendering it totally useless for our purposes. In other cases, however, the problem existed only for frequencies below about 1400 Hz. Above about 1400 Hz, the measured background noise levels were about the same across test sessions. When only the regions above about 1400 Hz are considered, it is easier to accept the conclusion that SOAEs were emerging in the right ear where none existed in the earliest records. ͑Whether the apparent SOAE at 797 Hz in the March and May 1997 data was present at the time of the baseline measurements is difficult to know because of the great variability in the low-frequency noise floor across test sessions.͒
The data of Fig. 1 are presented differently at the bottom of Fig. 2 , where the peak level at each of the four SOAE frequencies is plotted as a function of test session. This figure shows that, generally, these SOAEs grew in level up through the middle of 1997, and then declined. The onset of the decline was associated with the highest dose of estropipate administered and also with the addition of spironolactone and medroxyprogesterone to the drug regimen. Thus there are multiple possible explanations for the decline, but the obvious tests cannot be performed. Peak levels for the single identifiable SOAE in the left ear are also shown in Fig. 2 ; again, a maximum occurred just prior to the estrogen dose being raised to its highest value. ͑SOAE frequencies can drift slightly from session to session. All the peak levels shown in Fig. 2 are the largest values obtained within Ϯ2 frequency bins of the nominal frequency of the SOAE. Each frequency bin was 5.38 Hz in width.͒ Some of the variability in level seen across test sessions in these SOAEs is to be expected for such weak SOAEs ͑Probst et al., 1991͒. In addition, some of the variability may have resulted from variation in the concentration of the estrogenic drugs in the cochlea; SOAE intermittency has been seen in experiments involving other drugs that are active in the cochlea ͑e.g., McFadden and Plattsmier, 1984; McFadden and Pasanen, 1994͒ . While the OAE measurements were always made in the early evening, different amounts of time had elapsed since the last dose of one drug or another, and the effects of these differences are unknown.
The CEOAEs obtained from subject DJ showed no substantial change in overall level across test sessions. However, several frequency bands containing a ͑new͒ SOAE did increase, presumably because the SOAEs were being synchronized by the click trains ͑Probst et al., 1991͒. Some peaks in the CEOAE spectrum having no associated SOAEs also increased in level across test sessions. We remind the reader that this subject had considerable hearing loss in both ears.
Two tests of cognitive ability that show marked sex differences ͑Hampson and Kimura, 1992͒ were administered during each test session, but the results were inconclusive. Performance on a mental-rotation task showed small improvement ͑not the decline that might be expected to accompany demasculinization͒, but this may have been a general practice effect, even though care was taken not to reuse the same items for each test. There was also an improvement in a word-production task ͑the expected direction of effect to accompany feminization for this task͒, but the improvements were too small to be definitive.
III. DISCUSSION
There are multiple possible interpretations of these data. One parsimonious interpretation is that the SOAEs seen in the right ear after February 1997 are in fact new SOAEs, whose emergence is attributable to the estrogen treatment. Estrogen is administered to subjects of this sort both to reduce the androgen levels and to increase the estrogen levels in their bodies. The emergence of softer skin and larger breasts, the decrease in growth rate of body hair, and the loss of muscle mass in subject DJ is testimony to the effectiveness of this treatment. Previously, we have attributed the sex differences in the expression of OAEs to a suppressive action of androgens acting prenatally on the cochlear amplifiers ͑McFadden, 1993, 1998͒, although the actual mechanisms of this suppressive action are still unknown. In accord with this prenatal hormonal explanation is the fact that the patterns of sex and ear differences in OAEs are the same in infants and children as in adults ͑Burns et al., 1992; Norton, 1992͒ even though the sex differences in androgen levels are minimal, both at birth and again from about six months of age until the onset of puberty ͑see Smail et al., 1981͒. If these are new SOAEs that are attributable to the estrogen treatment, it would be desirable to know exactly what aspect of that treatment led to their emergence. One possibility ͓that is in accord with our previous suggestion about the suppressive effects of androgens ͑McFadden, 1993, 1998͔͒ is that androgens act suppressively on SOAEs both prenatally and in adulthood, and that the reduction in androgen levels experienced by subject DJ allowed those cochlear amplifiers having a tendency toward instability to go into oscillation, thereby giving rise to new SOAEs. ͑Said differently, androgens may act both organizationally and activationally to suppress SOAEs.͒ A weakness with this interpretation is that subject DJ's serum testosterone level fell only modestly during the time the SOAEs emerged, from 340 ng/dl prior to beginning estrogen therapy to 289 ng/dl in June 1997 ͑the normal range for males is 241-826 ng/dl͒. Currently, there is no evidence whether a change of that magnitude would be adequate to alter SOAEs. An alternative possibility is that the higher estrogen levels themselves were responsible for the emergence of these new SOAEs. The problem with this interpretation is that past research suggests that increases in estrogen level do not greatly affect SOAEs. Estrogen levels change through the menstrual cycle with little effect on SOAEs ͑Bell, 1992; Haggerty et al., 1993; Penner, 1995͒ , and estrogen levels increase dramatically through the course of pregnancy also with minimal apparent effect on SOAEs ͑Burns et al., 1993͒. Of course, the effects of androgens and estrogens may be different in adult male and female cochleas, making these facts misleading, but they do constitute current knowledge. At this time, it appears impossible to know whether the emergence of new SOAEs in our adult male subject is best attributable to the reduction in his androgen levels or the increase in his estrogen levels, but parsimony suggests the former.
A completely opposing interpretation is that the SOAEs seen in the right ear after February 1997 were not new, and only appeared to be new because of problems with the baseline data. SOAEs are affected by exposure to intense sounds ͑Norton et al., 1989; Penner, 1996͒, various common drugs ͑e.g., McFadden and Plattsmier, 1984; Pasanen, 1994͒, and other agents ͑Probst et al., 1991͒. Thus it is logically possible that the absence of SOAEs from the baseline data in Fig. 1 was temporary, and attributable to some unknown, short-term effect͑s͒ that dissipated by February 1997, allowing the SOAEs to reassert themselves, quite independent of any contribution from estrogen. Interpretations of this sort are common with case studies because adequate tests are often impossible to conduct, as is the case here. While it is currently impossible to know whether the SOAEs observed were new or not, we are presenting the data publicly now, in part because of our considerable uncertainty about whether, and when, another subject of this sort will become available to us for study.
Whether or not the SOAEs in subject DJ's right ear are new and were produced by the estrogen treatment, various facts about sex differences in OAEs suggest that high levels of androgens contribute to a male-like auditory periphery, both prenatally and in adulthood. Consequently, an important next step is to investigate the structural and functional effects of androgens and estrogens on the relevant cochlear structures during both prenatal and adult stages of life.
